source
- Safety concerns emerge as radiopharmaceuticals advance in cancer trialsRadiopharmaceuticals are being hailed for their ability to deliver radiation directly to tumours, potentially sparing surrounding healthy tissue and improving cancer therapy. However, as more cand…
- Silence brings the noise to Takeda with phase 2 blood cancer winA phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Th…Fierce Biotech · 15h ago↗ source
- BlossomHill and Latigo Biotherapeutics raise over 30% beyond IPO targets